Drugs / SV-101
last change Dec 2025 re-read 3 minutes ago

SV-101

Developed for
lung cancer · metastatic malignant neoplasm
Investigated by
Syncromune, Inc. · Williams Cancer Foundation

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05544240 Feb 2023 → Jul 2025 overdue lung cancer, metastatic malignant neoplasm Williams Cancer Foundation Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SV-101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05544240 ↗